GB201519194D0 - CGRP receptor antagonists - Google Patents

CGRP receptor antagonists

Info

Publication number
GB201519194D0
GB201519194D0 GBGB1519194.3A GB201519194A GB201519194D0 GB 201519194 D0 GB201519194 D0 GB 201519194D0 GB 201519194 A GB201519194 A GB 201519194A GB 201519194 D0 GB201519194 D0 GB 201519194D0
Authority
GB
United Kingdom
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1519194.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB1519194.3A priority Critical patent/GB201519194D0/en
Publication of GB201519194D0 publication Critical patent/GB201519194D0/en
Priority to CA3002625A priority patent/CA3002625A1/en
Priority to AU2016344689A priority patent/AU2016344689A1/en
Priority to JP2018541593A priority patent/JP6874014B2/ja
Priority to TW105135025A priority patent/TW201722936A/zh
Priority to EP16808804.5A priority patent/EP3368526B1/en
Priority to US15/336,893 priority patent/US9688660B2/en
Priority to ARP160103294A priority patent/AR106487A1/es
Priority to CN201680063940.2A priority patent/CN108430991B/zh
Priority to BR112018008416A priority patent/BR112018008416A2/pt
Priority to PCT/IB2016/056519 priority patent/WO2017072723A1/en
Priority to SG11201803382XA priority patent/SG11201803382XA/en
Priority to US15/588,051 priority patent/US9925178B2/en
Priority to US15/882,038 priority patent/US10166226B2/en
Priority to IL258894A priority patent/IL258894A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1519194.3A 2015-10-30 2015-10-30 CGRP receptor antagonists Ceased GB201519194D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1519194.3A GB201519194D0 (en) 2015-10-30 2015-10-30 CGRP receptor antagonists
SG11201803382XA SG11201803382XA (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists
US15/336,893 US9688660B2 (en) 2015-10-30 2016-10-28 CGRP receptor antagonists
CN201680063940.2A CN108430991B (zh) 2015-10-30 2016-10-28 Cgrp受体拮抗剂
JP2018541593A JP6874014B2 (ja) 2015-10-30 2016-10-28 Ｃｇｒｐ受容体アンタゴニスト
TW105135025A TW201722936A (zh) 2015-10-30 2016-10-28 Ｃｇｒｐ受體拮抗劑
EP16808804.5A EP3368526B1 (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists
CA3002625A CA3002625A1 (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists
ARP160103294A AR106487A1 (es) 2015-10-30 2016-10-28 Antagonistas de receptores de cgrp
AU2016344689A AU2016344689A1 (en) 2015-10-30 2016-10-28 CGRP receptor antagonists
BR112018008416A BR112018008416A2 (pt) 2015-10-30 2016-10-28 antagonistas do receptor cgrp
PCT/IB2016/056519 WO2017072723A1 (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists
US15/588,051 US9925178B2 (en) 2015-10-30 2017-05-05 CGRP receptor antagonists
US15/882,038 US10166226B2 (en) 2015-10-30 2018-01-29 CGRP receptor antagonists
IL258894A IL258894A (en) 2015-10-30 2018-04-24 Cgrp receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519194.3A GB201519194D0 (en) 2015-10-30 2015-10-30 CGRP receptor antagonists

Publications (1)

Publication Number Publication Date
GB201519194D0 true GB201519194D0 (en) 2015-12-16

Family

ID=55130446

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1519194.3A Ceased GB201519194D0 (en) 2015-10-30 2015-10-30 CGRP receptor antagonists

Country Status (13)

Country Link
US (3) US9688660B2 (https=)
EP (1) EP3368526B1 (https=)
JP (1) JP6874014B2 (https=)
CN (1) CN108430991B (https=)
AR (1) AR106487A1 (https=)
AU (1) AU2016344689A1 (https=)
BR (1) BR112018008416A2 (https=)
CA (1) CA3002625A1 (https=)
GB (1) GB201519194D0 (https=)
IL (1) IL258894A (https=)
SG (1) SG11201803382XA (https=)
TW (1) TW201722936A (https=)
WO (1) WO2017072723A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
CA3164445A1 (en) * 2019-12-17 2021-06-24 Biohaven Pharmaceutical Holding Company Ltd. Intranasal pharmaceutical compositions of cgrp inhibitors
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药（上海）有限公司 吲唑甲酰胺类衍生物及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
BRPI0311812B8 (pt) * 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
CA2549330A1 (en) 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
AU2005295855B2 (en) 2004-10-14 2011-08-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
AU2005299852B2 (en) 2004-10-22 2011-08-04 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
PE20080370A1 (es) 2006-06-08 2008-06-13 Boehringer Ingelheim Int Derivados de quinazolinona como antagonistas de cgrp
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
HUE025547T2 (en) * 2008-12-19 2016-02-29 Boehringer Ingelheim Int Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists

Also Published As

Publication number Publication date
TW201722936A (zh) 2017-07-01
US9688660B2 (en) 2017-06-27
BR112018008416A2 (pt) 2018-10-23
WO2017072723A1 (en) 2017-05-04
AU2016344689A1 (en) 2018-05-17
US9925178B2 (en) 2018-03-27
JP6874014B2 (ja) 2021-05-19
CA3002625A1 (en) 2017-05-04
EP3368526B1 (en) 2019-12-25
JP2018532790A (ja) 2018-11-08
US20170121311A1 (en) 2017-05-04
AR106487A1 (es) 2018-01-17
SG11201803382XA (en) 2018-05-30
US10166226B2 (en) 2019-01-01
US20180153876A1 (en) 2018-06-07
CN108430991B (zh) 2021-01-05
IL258894A (en) 2018-06-28
CN108430991A (zh) 2018-08-21
EP3368526A1 (en) 2018-09-05
US20170239236A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
SMT202100561T1 (it) Antagonisti di trpv4
IL258893A (en) Cgrp receptor antagonists
IL258737A (en) Antagonists ep4
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
ZA201800452B (en) Cgrp receptor antagonists
GB201702617D0 (en) Receptor
IL267686A (en) Integrin antagonists
IL244356A0 (en) Formulations for cgrp receptor antagonists
IL258894A (en) Cgrp receptor antagonists
GB201715008D0 (en) TRPV2 Antagonists
GB201702174D0 (en) Orexin receptor antagonists
EP3865472C0 (en) THROMBOXANE RECEPTOR ANTAGONISTS
IL252903A0 (en) cgrp antagonist peptides
GB201707499D0 (en) Orexin receptor antagonists
GB201507202D0 (en) Receptor tyosine kinase biomarkers
ZA201807767B (en) Angiotensin-1-receptor antagonists
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
ZA201704249B (en) Cgrp antagonist peptides
GB201707504D0 (en) Orexin receptor antagonists
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
TH1601001484A (th) สูตรผสมสำหรับ cgrp รีเซปเตอร์แอนตะกอนิสต์

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)